A mutation in the extracellular cysteine-rich repeat region of the β3 subunit activates integrinsαIIbβ3 and αVβ3

Inside-out signaling regulates the ligand-binding function of integrins through changes in receptor affinity and/or avidity. For example, alpha(IIb)beta(3) is in a low-affinity/avidity state in resting platelets, and activation of the receptor by platelet agonists enables fibrinogen to bind. In addition, certain mutations and truncations of the integrin cytoplasmic tails are associated with a high-affinity/avidity receptor. To further evaluate the structural basis of integrin activation, stable Chinese hamster ovary (CHO) cell transfectants were screened for high-affinity/avidity variants of alpha(IIb)beta(3) One clone (AM-1) expressed constitutively active alpha(IIb)beta(3), as evidenced by (1) binding of soluble fibrinogen and PAC1, a ligand-mimetic alpha(IIb)beta(3) antibody; and (2) fibrinogen-dependent cell aggregation. Sequence analysis and mutant expression in 293 cells proved that a single amino acid substitution in the cysteine-rich, extracellular portion of beta(3)(T562N) was responsible for receptor activation. In fact, T562N also activated alpha(v)beta(3), leading to spontaneous binding of soluble fibrinogen to 293 cells. In contrast, neither T562A nor T562Q activated alpha(IIb)beta(3) suggesting that acquisition of asparagine at residue 562 was the relevant variable. T562N also led to aberrant glycosylation of beta(3), but this was not responsible for the receptor activation. The binding of soluble fibrinogen to alpha(IIb)beta(3)(T562N) was not sufficient to trigger tyrosine phosphorylation of pp125(FAK), indicating that additional post-ligand binding events are required to activate this protein tyrosine kinase during integrin signaling. These studies have uncovered a novel gain-of-function mutation in a region of beta(3) intermediate between the ligand-binding region and the cytoplasmic tail, and they suggest that this region is involved in integrin structural changes during inside-out signaling. (C) 1999 by The American Society of Hematology.